Table 2 Patients’ baseline characteristics according to chemotherapy regimen and age
Age <70 years | Age ≥70 years | Age <75 years | Age ≥75 years | |||||
|---|---|---|---|---|---|---|---|---|
Characteristic | Monotherapy (n = 105) | Doublet (n = 1165) | Monotherapy (n = 104) | Doublet (n = 367) | Monotherapy (n = 146) | Doublet (n = 1396) | Monotherapy (n = 63) | Doublet (n = 136) |
Gender, n (%) | ||||||||
Male | 60 (57) | 739 (63) | 60 (58) | 234 (64) | 84 (58) | 888 (64) | 36 (57) | 85 (62) |
Female | 45 (43) | 426 (37) | 44 (42) | 133 (36) | 62 (42) | 508 (36) | 27 (43) | 51 (38) |
Median age, years (range) | 62 (23–69) | 61 (19–69) | 76 (70–100) | 73 (70–85) | 65 (23–74) | 63 (19–74) | 78 (75–100) | 77 (75–85) |
ECOG performance status, n (%) | (n = 103) | (n = 1144) | (n = 101) | (n = 362) | (n = 142) | (n = 1372) | (n = 62) | (n = 134) |
0 | 52 (50) | 435 (38) | 38 (38) | 112 (31) | 67 (47) | 514 (37) | 23 (37) | 33 (25) |
1 | 38 (37) | 599 (52) | 48 (48) | 199 (55) | 56 (39) | 719 (52) | 30 (48) | 79 (59) |
2 | 11 (11) | 108 (9) | 13 (13) | 41 (11) | 17 (12) | 129 (9) | 7 (11) | 20 (15) |
3 | 2 (2) | 2 (<1) | 2 (2) | 9 (2) | 2 (1) | 9 (1) | 2 (3) | 2 (1) |
4 | 0 | 0 | 0 | 1 (<1) | 0 | 1 (0) | 0 | 0 |
Metastatic site, n (%) a | ||||||||
Liver | 69 (66) | 849 (73) | 73 (70) | 253 (69) | 98 (67) | 1014 (73) | 44 (70) | 88 (64) |
Lung | 29 (28) | 323 (28) | 31 (30) | 100 (27) | 42 (29) | 385 (28) | 18 (29) | 38 (28) |
Bone | 1 (1) | 45 (4) | 2 (2) | 8 (2) | 2 (1) | 50 (4) | 1 (2) | 3 (2) |
Other | 32 (30) | 311 (27) | 22 (21) | 82 (22) | 41 (28) | 361 (25) | 14 (22) | 32 (23) |
No. of metastatic sites, n (%) | (n = 100) | (n = 1105) | (n = 102) | (n = 335) | (n = 140) | (n = 1317) | (n = 62) | (n = 123) |
1 | 73 (73) | 732 (66) | 78 (76) | 238 (71) | 104 (74) | 883 (67) | 47 (76) | 87 (71) |
>1 | 27 (27) | 373 (34) | 24 (24) | 97 (29) | 36 (26) | 434 (33) | 15 (24) | 36 (29) |
Local recurrence, % | 44 (45) | 526 (51) | 40 (42) | 176 (53) | 58 (42) | 638 (51) | 26 (46) | 64 (51) |
Median CEA, ng/mL (range) | (n = 92) | (n = 926) | (n = 91) | (n = 302) | (n = 126) | (n = 1113) | (n = 57) | (n = 115) |
19.8 (0.4–3312.7) | 21.2 (0–14671) | 13.7 (0.1–1175) | 21.9 (0.7–25305) | 17.2 (0.4–3312.7) | 20.9 (0–25305) | 22.7 (0.1–1175) | 25.6 (0.7–6848) | |
Prior chemotherapy, n (%) | (n = 53) | (n = 670) | (n = 47) | (n = 190) | (n = 73) | (n = 786) | (n = 27) | (n = 74) |
Adjuvant | 35 (66) | 453 (68) | 33 (70) | 127 (67) | 47 (64) | 534 (68) | 21 (78) | 46 (62) |
Neoadjuvant | 9 (17) | 67 (10) | 2 (4) | 24 (13) | 10 (14) | 79 (10) | 1 (4) | 12 (16) |